Scholar Rock

Scholar Rock is a biopharmaceutical company focused on developing therapies for serious diseases with high unmet needs. The company leverages advanced science to create life-changing treatments, particularly targeting the biology of protein growth factors, especially those in the transforming growth factor beta (TGFβ) superfamily. Scholar Rock's innovative approach involves developing niche modulators that selectively influence the activation of growth factors in the disease microenvironment. Founded by Professors Tim Springer and Leonard Zon, Scholar Rock is pioneering investigational therapies for conditions such as spinal muscular atrophy (SMA) and other diseases linked to growth factors. The company has achieved clinical proof-of-concept for a muscle-targeted treatment in SMA, showcasing its commitment to improving patient outcomes. With significant venture capital backing and a strong leadership team, Scholar Rock is well-positioned for growth and continues to advance its therapeutic programs through ongoing research and presentations at major conferences.